Subsequent investigations (NCT04032158) have been undertaken aimed at mitigating B cell activity as a means of slowing MS progression and have found that B cell inhibition is sufficient to reduce acute MS flares (Hauser et al., 2008; Reich et al., 2021), further underscoring the potential of BTK inhibition as a means of alleviating inflammation in both MS and other NDDs. Here, BTK is linked to myeloid sarcoma.